piezo type mechanosensitive ion channel component 2Genealiases: C18orf30 · C18orf58 · DA3 · DA5 · DAIPT · FAM38B
Q-omics provides the consensus-scored PIEZO2 profile across patient tissues and cancer cell-line models. PIEZO2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PIEZO2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PIEZO2 RNA expression shows 21,615 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where PIEZO2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIEZO2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIEZO2 survival associations across molecular data types. PIEZO2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIEZO2 RNA expression–survival associations across cancer types. High PIEZO2 expression shows unfavorable associations in KIRP, LUSC and STAD, but favorable associations in UCS, KIRC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PIEZO2 RNA expression.
This table summarizes PIEZO2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PIEZO2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIEZO2 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, HNSC, LIHC and THCA. The KIRC box plot shows higher PIEZO2 RNA expression in tumor versus normal tissue (log2 FC = +1.779, t-test p < 0.001).
This table shows molecular features associated with PIEZO2 in patient tissues and cancer cell lines. In patient samples, PIEZO2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PIEZO2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
